Guardion Health Sciences Completes Delivery of $875,000 Order to Malaysian Corporate Customer
June 30 2020 - 5:00AM
Guardion Health Sciences, Inc. (“Guardion” or the “Company”)
(Nasdaq: GHSI) announced today that it has completed shipment of
Astramern to Astramune Sdn Bhd, a subsidiary of Ho Wah Genting
Berhad (“HWGB”) (KLSE:9601), a Malaysian company listed on the
Malaysian Stock Exchange (Industrial Products sector). As such, the
Company will recognize this shipment in operating revenues during
the three months ending June 30, 2020. This order was previously
announced by the Company on April 1, 2020.
Astramern is a sister product to acuMMUNE™, the
Company’s proprietary immuno-supportive complex and the flagship
product of the Company’s recently-acquired NutriGuard™ business
line. acuMMUNE™ and Astramem are novel nutraceutical formulations
designed to support the body’s immune function – including
enhancing interferon-mediated anti-viral mechanisms and reducing
the inflammation associated with certain respiratory infections.
Additional information on acuMMUNE™ can be obtained at
https://www.nutriguard.com/acummune/.
Dr. David Evans, Ph.D., Guardion’s interim
President and Chief Executive Officer, commented, “We are pleased
to announce the successful fulfillment of our first significant
corporate order for our immune support product line. We believe
that this demonstrates our ability to design, manufacture and
deliver large-scale orders that originate from our NutriGuard™
brand, which was accomplished in spite of the operational and
logistical challenges faced by traditional manufacturers in this
current challenging business environment. Our team is continuing to
evaluate other similar business opportunities in the Far East and
elsewhere.”
Dr. Evans concluded. “I want to thank our entire
team, and particularly Dr. Mark McCarty, the original founder of
NutriGuard™, and now a senior scientist/consultant to Guardion, who
led the development of this proprietary formulation.”
About Guardion Health Sciences,
Inc.
Guardion is a specialty health sciences company
(i) that develops medical foods and medical devices in the ocular
health marketplace and (ii) that is developing nutraceuticals that
the Company believes will provide medicinal and health benefits to
consumers. Information and risk factors with respect to Guardion
and its business, including its ability to successfully develop and
commercialize its proprietary products and technologies, may be
obtained in the Company’s filings with the SEC at www.sec.gov.
About NutriGuard™
NutriGuard™ formulates high-quality
nutraceuticals, which are designed to supplement consumers’ diets.
NutriGuard uses industry standards to establish the safety and
efficacy of the products it develops and markets, maintains that
commitment through prudent manufacturing and quality assurance
programs, and only uses manufacturers who comply with FDA current
Good Manufacturing Practices (cGMP) requirements. Guardion plans to
increase NutriGuard’s existing customer base and build on its
product platform by making NutriGuard products available to
patients directly and through recommendations by their
physicians.
About VectorVision®
VectorVision® specializes in the standardization
of contrast sensitivity, glare sensitivity, low contrast acuity,
and ETDRS acuity vision testing. Its patented standardization
system provides the practitioner or researcher the ability to
delineate very small changes in visual capability, either as
compared to the population or from visit to visit. VectorVision’s®
patented technology is considered the standard of care for clinical
trials. VectorVision® is a wholly owned subsidiary of Guardion.
Forward-Looking Statement
Disclaimer
With the exception of the historical information
contained in this news release, the matters described herein may
contain forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended. Statements
preceded by, followed by or that otherwise include the words
“believes,” “expects,” “anticipates,” “intends,” “projects,”
“estimates,” “plans” and similar expressions or future or
conditional verbs such as “will,” “should,” “would,” “may” and
“could” are generally forward- looking in nature and not historical
facts, although not all forward-looking statements include the
foregoing. These statements involve unknown risks and uncertainties
that may individually or materially impact the matters discussed
herein for a variety of reasons that are outside the control of the
Company, including, but not limited to, the Company’s ability to
raise sufficient financing to implement its business plan, the
impact of the COVID-19 pandemic on the Company’s business,
operations and the economy in general, and the Company’s ability to
successfully develop and commercialize its proprietary products and
technologies. Readers are cautioned not to place undue reliance on
these forward- looking statements, as actual results could differ
materially from those described in the forward-looking statements
contained herein. Readers are urged to read the risk factors set
forth in the Company’s filings with the SEC, which are available at
the SEC’s website (www.sec.gov). The Company disclaims any
intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
Investor Relations Contact: Porter, LeVay
& Rose, Inc.
Michael PorterTelephone:(212)
564-4700E-mail:mike@plrinvest.com
Guardion Health Sciences (NASDAQ:GHSI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Guardion Health Sciences (NASDAQ:GHSI)
Historical Stock Chart
From Apr 2023 to Apr 2024